How is RET fusion-positive non–small cell lung cancer (NSCLC) treated?

Updated: Jul 15, 2021
  • Author: Winston W Tan, MD, FACP; Chief Editor: Nagla Abdel Karim, MD, PhD  more...
  • Print

For patients with RET fusion-positive NSCLC, the following agents are used:

  • Selpercatinib (Retevmo) [preferred]
  • Pralsetinib (Gavreto) [preferred]
  • Cabozantinib (Cabometyx) 
  • Vandetanib (Capresla)

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!